Abstract: Coating compositions comprise: a B-staged reaction product of one or more compounds comprising: a core chosen from C6-50 carbocyclic aromatic, C2-50 heterocyclic aromatic, C1-20 aliphatic, C1-20 heteroaliphatic, C3-20 cycloaliphatic, and C2-20 heterocycloaliphatic, each of which may be substituted or unsubstituted; and two or more substituents of formula (1) attached to the core: wherein: Ar1 is an aromatic group independently chosen from C6-50 carbocyclic aromatic and C2-50 heteroaromatic, each of which may be substituted or unsubstituted; Z is a substituent independently chosen from OR1, protected hydroxyl, carboxyl, protected carboxyl, SR1, protected thiol, —O—C(?O)—C1-6 alkyl, halogen, and NHR2; wherein each R1 is independently chosen from H, C1-10 alkyl, C2-10 unsaturated hydrocarbyl, and C5-30 aryl; each R2 is independently chosen from H, C1-10 alkyl, C2-10 unsaturated hydrocarbyl, C5-30 aryl, C(?O)—R1, and S(?O)2—R1; x is an integer from 1 to the total number of available aromatic ring atoms in Ar1

Abstract: A fracturing apparatus includes: a plunger pump having a hydraulic end and a power end, wherein the power end comprises a power end oil outlet and at least one power end oil inlet that are coupled to each other; a power end lubricating system, including a lubricating oil tank defining an accommodation space, at least one lubrication pump having a lubrication pump oil inlet and a lubrication pump oil outlet that are coupled to each other, and at least one lubrication motor configured to provide power for the at least one lubrication pump; a temperature detector disposed on any one of the oil return pipeline, the power end oil outlet, and the lubricating oil tank; and a control system connected to the temperature detector and the power end lubricating system and configured to control the power end lubricating system.

Abstract: A photoresist underlayer composition, comprising a polymer comprising a repeating unit of formula (1): wherein Ar is a monocyclic or polycyclic C5-60 aromatic group, wherein the aromatic group comprises one or more aromatic ring heteroatoms, a substituent group comprising a heteroatom, or a combination thereof; R1 is hydrogen, substituted or unsubstituted C1-30 alkyl, substituted or unsubstituted C1-30 heteroalkyl, substituted or unsubstituted C3-30 cycloalkyl, substituted or unsubstituted C2-30 heterocycloalkyl, substituted or unsubstituted C2-30 alkenyl, substituted or unsubstituted C2-30 alkynyl, substituted or unsubstituted C6-30 aryl, substituted or unsubstituted C7-30 arylalkyl, substituted or unsubstituted C7-30 alkylaryl, substituted or unsubstituted C3-30 heteroaryl, or substituted or unsubstituted C4-30 heteroarylalkyl; and R2 is substituted or unsubstituted C1-30 alkyl, substituted or unsubstituted C1-30 heteroalkyl, substituted or unsubstituted C3-30 cycloalkyl, substituted or unsubstituted C2

Abstract: A fracturing apparatus includes a motor, a first plunger pump, a power supply platform, a gas turbine engine, a generator, and one or more rectifiers. At least two of the gas turbine engine, the generator, and the one or more rectifiers are arranged on the power supply platform. A first end of the generator is connected to the gas turbine engine. A second end of the generator is connected to the one or more rectifiers. The generator is configured to output a voltage to the one or more rectifiers. The one or more rectifiers are configured to provide power to the motor.

Abstract: A fracturing apparatus may include a first plunger pump including a first power end and a first hydraulic end; a prime mover including a first power output shaft; and a first clutch including a first connection portion and a second connection portion. The first power end of the first plunger pump includes a first power input shaft, the first connection portion is coupled to the first power input shaft, the second connection portion is coupled to the first power output shaft of the prime mover.

Abstract: The present invention provides new methods for preparing compound 5, and pharmaceutically acceptable salts thereof, of structure Compound 5, or a pharmaceutically acceptable salt thereof, is an important intermediate in the synthesis of carfilzomib. The invention further provides methods of making a useful manganese catalyst that may be used in the epoxidation step of the present invention.

Abstract: Fracturing equipment includes an electric-driven apparatus and an electric-power supply apparatus. The electric-driven apparatus includes at least one motor, at least one lubrication module, and at least one heat dissipation module. The electric-power supply apparatus includes a first electric-power supply and a second electric-power supply, where the at least one motor is powered by the first electric-power supply, and the at least one lubrication module and the at least one heat dissipation module are powered by at least one of the first electric-power supply or the second electric-power supply.

Abstract: A fracturing apparatus may include a power supply platform; a gas turbine engine; a generator; and one or more rectifiers. At least two of the gas turbine engine, the generator, and the one or more rectifiers are arranged on the power supply platform. A first end of the generator is connected to the gas turbine engine. A second end of the generator is connected to the one or more rectifiers. The generator is configured to output a voltage to the one or more rectifiers.

Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Compound F can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.

Abstract: A fracturing apparatus is provided. The fracturing apparatus includes: a plunger pump including a hydraulic end and a power end, the power end having a power end oil outlet and at least one power end oil inlet that are coupled to each other; and a power end lubricating system, including: a lubricating oil tank configured for defining an accommodation space, at least one lubrication pump having a lubrication pump oil inlet and a lubrication pump oil outlet that are coupled to each other, and at least one lubrication motor configured for providing power for the at least one lubrication pump, wherein at least a portion of at least one of the lubrication motor and the lubrication pump is located in the accommodation space.

Abstract: Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.

Abstract: An actuator for adjusting a display terminal and a vehicle are provided. The actuator includes: a mounting unit configured to mount a display terminal; a clutch unit, a first engaging portion of the clutch unit being connected to the mounting unit, and a second engaging portion of the clutch unit being normally interlocked with the first engaging portion; and a drive unit, an output end of the drive unit being connected to the second engaging portion.

Abstract: Disclosed herein is an improved process for the synthesis of compound (A): (A), or a salt or solvate thereof via methylation of compound (B): (B), or a salt or solvate thereof, a crystalline hydrate of compound A, and pharmaceutical formulations comprising a crystalline hydrate of compound (A).

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.